Bedaquiline fumarate

• CAT Number: I005055
• CAS Number: 845533-86-0
• Molecular Formula: C36H35BrN2O6
• Molecular Weight: 671.58
• Purity: ≥95%
• Synonyms: Sirturo
• Target: Bacterial
• Solubility: 10 mM in DMSO
• Storage: 3 years -20C powder
• IC50: 10nM
• IUPAC Name: (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol;(E)-but-2-enedioic acid
• InChI: InChI=1S/C32H31BrN2O2.C4H4O4/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3;5-3(6)1-2-4(7)8/h4-17,20-21,30,36H,18-19H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t30-,32-;/m1./s1
• InChIKey: ZLVSPMRFRHMMOY-WWCCMVHESA-N
• SMILES: CN(C)CC[C@@](C1=CC=CC2=CC=CC=C21)([C@H](C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O.C(=C/C(=O)O)\C(=O)O

Bedaquiline fumarate (Cat No.:I005055) is a medication used for the treatment of drug-resistant tuberculosis (TB). It belongs to a class of drugs known as diarylquinolines and works by inhibiting the activity of an enzyme called ATP synthase, which is essential for the survival of Mycobacterium tuberculosis, the bacteria that causes TB. Bedaquiline is specifically indicated for the treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) in combination with other anti-TB drugs. It is considered a significant advancement in TB treatment, especially for patients with limited treatment options due to resistance to standard TB drugs. Bedaquiline is typically used as part of a combination regimen and has shown efficacy in improving treatment outcomes for drug-resistant TB.

Overview of Clinical Research

Bedaquiline fumarate (Sirturo) is approved by the U.S. Food and Drug Administration (FDA) for use as part of a combination therapy in adults with pulmonary multidrug-resistant tuberculosis (MDR TB) when an effective treatment regimen cannot otherwise be provided.Bedaquiline may be used to treat adults ( 18 years) with a confirmed diagnosis of pulmonary MDR TB.

Reference

1. Lakshmanan M, et al. Bedaquiline – The first ATP synthase inhibitor against multi drug resistant tuberculosis. J Young Pharm. 2013 Dec;5(4):112-115.
2. Chahine EB, et al. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother. 2014 Jan;48(1):107-15.
3.Belosludtsev, Konstantin N., et al. "BBA-Biomembranes." channels 2: 14.